SAFETY OF A NEW PERTUSSIS VACCINE CANDIDATE BASED ON BORDETELLA PERTUSSIS OUTER MEMBRANE VESICLES

DAVID SABATER MARTINEZ; MARÍA EMILIA GAILLARD; GRISELDA MORENO; DANIELA BOTTERO ; AGUSTINA ERREA ; EUGENIA ZURITA; ERIKA BARTEL; MARTIN RUMBO; DANIELA HOZBOR

Congreso; IV LASID Meeting LXIII Argentinean Immunology Society Meeting II French-Argentinean Immunology Meeting; 2015

Pertussis is acurrent public health problem even in countries with high vaccination coverage.This alarming situation calls for the implementationof new strategies for the disease control. Under this context we designed a newvaccine based on outer membrane vesicles (OMVs) derived from Bordetella pertussis which behaved in ananimal model as a very good vaccine candidate. In this work we evaluated theOMVs-vaccine safety. We performed the mouse weight gain test (MWG) anddetermined the levels of IL-6 used as indicator of proinflammatory response. Humanwhole blood IL-6 release assays were also used to estimate the endotoxicactivities of OMVs-vaccine. For the MWG-test, groups of 8 Balb/c mice outbredmice were i.p. vaccinated with OMVs-vaccine or commercial pertussis vaccines. Allvaccine formulations fulfilled the WHO criteria of safety for this test. Miceimmunized with OMVs vaccine underwent only small weight loss (less than 1.5% ofthe original weight) at 16 h, but at 3 days after vaccination, all treated miceregained their weight. The levels of IL-6 showed a rise to 306.21 ± 49.6 pg/mLat 4h post immunization with OMVs-vaccine. For the commercial acellular vaccineused at 1/10 of the human dose, 69.14 ± 9.42 pg/mL was detected. Higher levelswere detected with whole-cell vaccine (wP, 6,225 ± 1,554.12 pg/ml). IL-6mesurements performed in human blood assays showed similar trends for OMVs-vaccine(12-fold lower release than with wP). In conclusion, our OMVs-vaccine seems tobe a safe vaccine candidate against pertussis.